# Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

> **NCT00093639** · PHASE1,PHASE2 · COMPLETED · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Leukemia

## Interventions

- **DRUG:** everolimus
- **DRUG:** imatinib mesylate

## Key facts

- **NCT ID:** NCT00093639
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2006-08
- **Final completion:** 2006-08
- **Target enrollment:** — (—)
- **Last updated:** 2013-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00093639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00093639, "Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate". Retrieved via MORVS 2026-09-29 from https://api.morvs.ai/clinical/NCT00093639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*